Novartis, the Swiss pharmaceuticals giant, has reported a 3% increase in sales for the second quarter of 2026, reaching $14.4 billion. This performance slightly surpassed analyst forecasts of $14 billion. The growth is largely attributed to the successful launch of new products, including Rhapsido, a treatment for chronic rashes, which has already generated $64 million in sales since its approval in the US and EU.
Despite facing patent expirations for key drugs like Entresto, a heart failure treatment that generated $7.7 billion in 2025, Novartis has managed to maintain strong sales. The company confirmed its targets for 2026 and aims for 'low single-digit' sales growth for the entire year.
However, net profit fell by 19% to $3.2 billion, primarily due to higher interest and tax expenses. The Basel-based company remains optimistic about its future performance, driven by the success of its new treatments.
Novartis's performance in the second quarter highlights the company's ability to adapt to market challenges, including patent expirations, by introducing new products that resonate with patients and healthcare providers.
The pharmaceutical industry is witnessing a shift towards innovative treatments, and Novartis's recent success underscores the importance of continuous research and development in maintaining a competitive edge.
